ENROLLING NOW A Phase 2 Clinical Study for Metastatic Non-Small Cell Lung Cancer (NSCLC) LUN-202 is a Phase 2, multicenter clinical trial for patients whose current chemoimmunotherapy for NSCLC has stopped working. The trial is determining whether an investigational one-time immunotherapy treatment ...
Dr Gupta on Considerations for Frontline Treatment Selection in HR+/HER2-Negative Breast Cancer Dr Alawadhi on the Link Between Obesity/Overweight and Breast Cancer Outcomes Dr Rimm on How FDA-Approved IHC Tests Pose Reproducibility Challenges in Breast Cancer ...
non-small cell lung cancer (NSCLC) patients who took the drug had “median overall survival almost double that of standard of care chemotherapy.” The company noted that it had scheduled a meeting with the Food and Drug Administration to discuss submitting an application for the approval of the...
Thus, we believe that methods to enrich for these TIL populations, such as Iovance’s next generation TILs could be critical to drive better clinical responses.” As NSCLC is a notoriously difficult indication to address, Pantginis argues that the results should be interpreted as a major ...
In 2017, the FDA approved the first CAR-T cell therapy for large B-cell lymphoma with upregulated CD19 surface protein and so far, four other CAR-T cell therapies have been approved by the FDA. It is an exciting time for cell therapies. The upcoming years will show whether current ...
Annalee Armstrong MORE ON THIS TOPIC Cardiovascular disease Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner February 28, 2025 · 2 min read · Tristan Manalac Pipeline Mission Nixes Preclinical Studies, Falls Back on Clinical Candidates ...
Currently, the PD-1 inhibitor nivolumab (Opdivo) combined with the CTLA-4 inhibitor ipilimumab (Yervoy) remains the only approved immunotherapy combination. However, research into combination approaches is now focusing on triplets of antiPD-1 therapies and new checkpoints, such as IDO, Robert ...